Acutaas Chemicals Limited Stock Price Valuation Analysis as on June 2026
Acutaas Chemicals Limited — rechristened from the well-regarded Ami Organics Limited in May 2025 — is one of India’s most sophisticated R&D-driven specialty chemical manufacturers. Founded in Surat, Gujarat in 2004, the company has over two decades of institutional expertise in complex organic synthesis, and today operates four GMP-compliant, USFDA-approved manufacturing facilities in Gujarat (Sachin, Ankleshwar, Jhagadia) and Uttar Pradesh, with an installed reactor capacity exceeding 1,200 KL. Its product portfolio spans more than 610 commercialized molecules, exported to 55+ countries across the Americas, Europe, and Asia.
The business is organized around three evolving verticals. The core Advanced Pharmaceutical Intermediates segment — contributing approximately 85% of FY25 revenues — manufactures high-complexity intermediates for regulated and generic APIs spanning anti-retroviral (Dolutegravir, Rivaroxaban), anti-Parkinsonian (Entacapone), anti-cancer (Nintedanib), and anti-psychotic (Trazodone) applications. Critically, 91% of its products serve the structurally growing chronic disease segment, insulating revenues from the volatility typical of acute-care API cycles.
The second vertical — Specialty & Fine Chemicals — covers agrochemical key starting materials, parabens, cosmetic actives, and industrial process chemicals. The nascent but high-potential third vertical encompasses Battery Electrolyte Additives (Vinylene Carbonate / VC and Fluoroethylene Carbonate / FEC, each with 2,000 MT installed capacity inaugurated January 2026) and Semiconductor Photoresist Chemicals, positioning Acutaas at the intersection of India’s emerging deep-tech supply chain ambitions.
The company’s CDMO business is a structural differentiator. A landmark long-term contract with Fermion OY (Orion Corporation’s CDMO arm, Finland) validates the quality and scalability of the Ankleshwar DCS-equipped facility. Revenue is geographically balanced — approximately 50% from emerging markets and 40% from regulated markets (USA, EU, Japan) — with exports contributing over 56% of FY24 revenues. The company holds EcoVadis Platinum Medal ESG recognition and has crossed the ₹1,000 Cr revenue milestone in FY25, with FY26 delivering ₹1,339 Cr.
Acutaas has compounded revenue at a CAGR of ~41% between FY20–FY26, accelerating sharply from FY25 onward as the Ankleshwar facility reached full capacity and CDMO ramp-up kicked in. FY26 was the company’s strongest year on record — revenue at ₹1,339 Cr (+33% YoY), EBITDA at ₹480 Cr (+107% YoY), PAT at ₹356 Cr (+122% YoY). Operating leverage is clearly visible: EBITDA margins expanded from 17.9% in FY24 to 23.0% in FY25 and 35.9% in FY26, reflecting the high-margin CDMO contracts and improved product mix.
| Metric (₹ Cr) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26A |
|---|---|---|---|---|---|---|
| Revenue | 340.6 | 520.1 | 616.7 | 717.5 | 1,006.9 | 1,339.4 |
| Revenue Growth % | 42.1% | 52.7% | 18.6% | 16.3% | 40.3% | 33.0% |
| Raw Materials | 179.5 | 272.8 | 330.9 | 411.7 | 552.2 | 535.8 |
| Employee Cost | 21.0 | 41.4 | 48.8 | 63.1 | 83.7 | 92.0 |
| EBITDA | 80.2 | 105.2 | 122.6 | 128.5 | 232.1 | 480.4 |
| EBITDA Margin % | 23.5% | 20.2% | 19.9% | 17.9% | 23.0% | 35.9% |
| Depreciation | 14.5 | 25.8 | 31.2 | 40.1 | 52.4 | 58.0 |
| EBIT | 65.7 | 79.4 | 91.4 | 88.4 | 179.7 | 422.4 |
| PAT | 48.5 | 79.3 | 88.5 | 42.8 | 160.4 | 356.4 |
| PAT Margin % | 14.2% | 15.2% | 14.3% | 6.0% | 15.9% | 26.6% |
| EPS (₹) | 5.9 | 9.7 | 10.8 | 5.2 | 19.5 | 43.3 |
| Dividend/Share (₹) | 1.0 | 1.5 | 1.5 | 1.5 | 1.5 | 2.5 |
| ROE % | — | — | 14.9% | ~8% | 17.4% | ~24% |
| ROCE % | — | — | 15.0% | ~10% | 15.4% | ~20% |
Note: FY24 PAT dip reflects one-time transition costs from Ankleshwar brownfield ramp-up and acquisition charges (Gujarat Organics, BFC). Financials are consolidated. FY26A = audited actuals (April 30, 2026 board meeting).
Balance sheet discipline is exceptional. Debt-to-equity stands at 0.01x, net cash position of ~₹240 Cr (FY26), and capex for FY26 of ~₹220 Cr was funded entirely through internal accruals. The company raised ₹500 Cr via QIP in FY25 to fund the Ankleshwar expansion and the Indochem JV (battery electrolytes, South Korea). Working capital is under control; receivables and inventory cycles are typical of specialty pharma intermediates exporters.
The DCF model projects free cash flows over a 10-year horizon using FY26 as the base year. Revenue grows at 25% in FY27 (management guidance), tapering to 18% in FY28–29 as new verticals mature, and normalizes to 12% by FY31–33, before moderating to the 5% terminal rate. EBITDA margins are held at 34–36% reflecting the richer CDMO mix. Capex intensity assumed at ~8–10% of revenues in expansion years, declining to 5% terminal. WACC of 12% (risk-free rate 7.2%, equity risk premium 5.8%, beta 1.0, minimal debt). Terminal growth rate: 5%.
The DCF implies fair value in the ₹2,250–2,550 band — a ~7–18% discount to the current market price of ₹2,731. At CMP, the stock prices in ~25% revenue CAGR execution with sustained 35%+ margins. The valuation is defensible only if battery and semiconductor verticals contribute meaningfully by FY28, as management intends.
Acutaas trades at a meaningful premium to most specialty pharma intermediate peers, justified by its superior growth trajectory, CDMO optionality, and diversification into battery materials. However, the gap versus slower-growing peers is material, and any execution miss on new verticals could compress multiples sharply.
| Company | Mkt Cap (₹ Cr) | Rev FY26 (₹ Cr) | Rev Growth % | EBITDA Margin | P/E (TTM) | EV/EBITDA | P/B | ROCE |
|---|---|---|---|---|---|---|---|---|
| Acutaas Chemicals | 22,531 | 1,339 | 33% | 35.9% | 63x | 47x | 13.6x | 20% |
| Aether Industries | ~7,800 | ~780 | ~18% | ~25% | ~55x | ~35x | ~6x | ~15% |
| Neuland Laboratories | ~12,500 | ~1,450 | ~22% | ~22% | ~45x | ~30x | ~8x | ~18% |
| Supriya Lifescience | ~5,200 | ~620 | ~15% | ~30% | ~38x | ~25x | ~5x | ~16% |
| Aarti Pharmalabs | ~4,800 | ~1,100 | ~12% | ~18% | ~32x | ~22x | ~3x | ~12% |
| Granules India | ~8,200 | ~4,200 | ~14% | ~16% | ~28x | ~18x | ~3x | ~14% |
| Sector Median | ~7,800 | ~1,000 | ~16% | ~22% | ~40x | ~27x | ~5x | ~15% |
Acutaas commands a 55–70% P/E premium to sector median and a significant EV/EBITDA premium. The premium is partially warranted given its 33% revenue growth (sector median ~16%), 35.9% EBITDA margins (sector median ~22%), and unique exposure to battery electrolyte additives and semiconductor chemicals — categories where no Indian-listed peer has meaningful revenue. The 3-year historical average P/E of ~72x suggests the current 63x TTM P/E is, unusually, slightly below its own historical average — offering a relative entry point, though not a cheap one in absolute terms.
Acutaas’s net worth (book value) as of FY26-end is estimated at approximately ₹1,650–1,700 Cr (post the QIP and retained earnings build-up). With ~8.25 Cr shares outstanding, book value per share is approximately ₹200–206. The stock trades at ~13.6x P/B, consistent with high-quality specialty chemical companies with strong return ratios. A replacement-cost NAV analysis of the four facilities (gross block ~₹1,200 Cr, net ~₹750 Cr), plus net cash of ₹240 Cr, investments in subsidiaries, and net working capital, yields a conservative NAV of approximately ₹1,100–1,200/share. At CMP ₹2,731, the stock trades at ~2.3x replacement NAV — implying the market is pricing substantial intangible value (molecular IP, regulatory clearances, customer relationships, CDMO pipeline). This is typical and rational for a platform specialty chemical company; the NAV floor is not a relevant anchoring price at this growth stage.
EPV assumes no growth and capitalizes normalized sustainable earnings at the cost of capital. Using FY26 EBIT of ~₹422 Cr, adjusted for a normalized tax rate of 25%, normalized EBIT after tax = ~₹317 Cr. Capitalizing at WACC of 12% yields EPV enterprise value of ~₹2,640 Cr. Adding net cash of ₹240 Cr and dividing by 8.25 Cr shares gives EPV per share of approximately ₹350–380. The CMP of ₹2,731 implies the market ascribes ~88% of current valuation to future growth optionality — structurally reasonable for a company growing revenues at 30%+ with new verticals set to contribute from FY27. EPV serves as a theoretical downside floor in a zero-growth scenario; it is not a realistic investment case target.
Acutaas is evolving from a pure-play pharma intermediate manufacturer into a multi-vertical specialty chemicals platform. SOTP is increasingly relevant as the new verticals mature.
| Segment | FY26 Rev Est. (₹ Cr) | % of Total | Valuation Method | Multiple / Basis | Segment EV (₹ Cr) | Value/Share (₹) |
|---|---|---|---|---|---|---|
| Advanced Pharma Intermediates (CDMO incl.) | ~1,150 | 86% | EV/Revenue | 18x | 20,700 | 2,509 |
| Specialty & Fine Chemicals | ~120 | 9% | EV/Revenue | 8x | 960 | 116 |
| Battery Electrolyte (VC / FEC — nascent) | ~50 | 4% | EV/Revenue (growth premium) | 25x | 1,250 | 152 |
| Semiconductor Chemicals (early stage) | ~20 | 1% | EV/Revenue (optionality) | 30x | 600 | 73 |
| Net Cash & Investments | — | — | Book Value | 1x | 240 | 29 |
| SOTP Enterprise Value | ₹1,340 Cr | 100% | — | — | 23,750 | 2,879 |
The SOTP analysis yields an implied value of approximately ₹2,879 per share — broadly in line with the current market price. This suggests the market is fairly pricing the existing business mix. Meaningful upside from here requires either battery/semiconductor verticals to scale faster than modeled, or the CDMO revenue from Ankleshwar to surprise on margins. The SOTP also highlights the significant optionality premium the market is assigning to battery and semiconductor chemicals, where revenues are still nascent.
Given the premium valuation and strong growth visibility, a disciplined accumulation strategy is warranted. The buy range is derived from a blended DCF/peer multiple framework with a 10–15% margin of safety from intrinsic value.
15–20% discount to intrinsic value; ideal for meaningful position building. Likely triggered only on broad market weakness or stock-specific concern.
Within fair value band; prudent for SIP-style staggered buying over 2–3 tranches. Reward/risk remains favourable at 3–5 year horizon.
CMP falls here. Fully valued on near-term earnings; hold existing positions. Fresh buying requires conviction on FY27–28 new-vertical execution.
Start trimming on strong rally here; valuations reach 65–70x FY27E. Book partial profits, retain core position.
Valuations become speculative (75–85x forward). Exit if growth guidance has been met and no new catalyst emerges.
A fall below ₹1,900 without fundamental deterioration is a buying opportunity, not a sell trigger. Exit only if Fermion contract cancelled or regulatory embargo on facilities.
Speculative Re-rating
If the stock breaches ₹3,800+ on momentum without corresponding EPS upgrade, the P/E would exceed 85x on FY27E earnings — historically unsustainable. A disciplined exit locks in gains before any mean reversion.
Growth Guidance Miss
A quarterly revenue growth below 18% YoY for two consecutive quarters (vs. guidance of 25%), or EBITDA margin compression below 26% sustained over 2 quarters, signals structural deterioration and warrants an exit.
Regulatory / Contractual Risk
A USFDA Form 483 with critical observations on any facility, or loss / non-renewal of the Fermion CDMO contract, would materially impair 15–20% of revenue and compress premium valuation. Exit swiftly in such scenario.
1. CDMO Scale-Up at Ankleshwar: The new DCS-automated Ankleshwar facility with 442 KL capacity is fully operational as of FY25. This is the single largest growth driver — CDMO revenues from Fermion and other long-term contracts will progressively fill utilization through FY27–28, driving margin expansion through operating leverage on high-value molecules.
2. Battery Electrolyte Additives (VC & FEC): Inaugurated in January 2026, the 2,000 MT each capacity for Vinylene Carbonate and Fluoroethylene Carbonate targets the global Li-ion battery electrolyte market — a segment growing at 25%+ CAGR driven by EV adoption. Acutaas has secured long-term export agreements for these products. Management expects this segment to contribute from Q1 FY27 onwards, with ₹200–300 Cr in revenue by FY28.
3. Semiconductor Photoresist Chemicals: India’s semiconductor ambitions (₹76,000 Cr PLI + ISMC, CG Power fabs) create domestic demand for photoresist intermediates. Acutaas’s early mover position — with a dedicated Sachin pilot plant expected operational by Q3 FY26 — gives it a structural advantage. Revenues will be small initially but command premium multiples given the technology barrier to entry.
4. Indochem JV (South Korea): A joint venture with a South Korean chemical partner (Indochem) adds geographic reach and technology access for electrolyte and specialty chemical manufacturing. The ₹130 Cr JV investment enhances Acutaas’s position in the Korea-Japan regulated market corridor — critical for battery-grade specialty chemicals.
5. NCE Pipeline & New API Intermediates: With 610+ commercialized products and a robust R&D pipeline, Acutaas continuously introduces new molecules. The NCE intermediate segment carries the highest margins and is the primary long-term revenue compounder, serving innovator pharma companies in the US and Europe with patent-protected molecules during their development and early commercialization phase.
FY27 Guidance: Management has guided for 25% revenue growth in FY27 (implying ~₹1,675 Cr), with EBITDA margins broadly maintained at FY26 levels (~35%). Analyst consensus forecasts 23–25% revenue CAGR and 23–25% EPS CAGR over the next three years, implying FY28E EPS of approximately ₹65–70.
- Battery electrolyte (VC/FEC) revenues ramp faster than expected from Q1 FY27
- New CDMO contract announcements from major global pharma players
- Semiconductor photoresist pilot plant successfully commercializes
- Indochem JV secures anchor orders from Korean battery manufacturers
- China+1 / supply chain diversification accelerates Indian pharma intermediate demand
- USFDA Green Light / drug master file approvals open new regulated market avenues
- Margin upside if input (raw material) costs decline amid softer commodity cycle
- Index inclusion (Nifty 200 / Nifty 500) triggers passive fund inflows
- Rich valuation (63x P/E) leaves no room for execution error; any guidance cut = sharp de-rating
- Promoter holding at 32.7% — modest skin-in-game; further dilution risk from future fundraises
- USFDA warning letter or Form 483 critical observations on any GMP-approved facility
- Fermion contract non-renewal or volume reduction would remove ~15–20% of CDMO visibility
- Battery chemicals demand slower than projected; global EV adoption headwinds
- Chinese specialty chemical dumping disrupting pharma intermediate pricing
- Raw material cost inflation (key solvents, reagents) squeezing gross margins
- Currency risk: USD/INR movement impacts export realisations (~56% export revenue)
This analysis suggests an Accumulate on Dips posture for investors who do not hold the stock, with staggered entry in the ₹2,150–2,500 band being the zone of adequate reward-to-risk. For existing holders, the recommendation is to Hold with a 3-year horizon and a target range of ₹3,100 (base) to ₹3,800 (bull). The thesis rests on three pillars materializing: (a) Ankleshwar CDMO capacity reaching 70%+ utilization by FY27, (b) battery electrolyte revenues crossing ₹200 Cr by FY28, and (c) at least one semiconductor photoresist customer announcement. If these materialize, the stock warrants a re-rating to 55–60x FY28E earnings, implying a base-case target of ₹3,575–3,900 by 2028. Risk management is paramount — any USFDA adverse action or Fermion contract disruption would require an immediate reassessment of the thesis.
